Fractional CO2 Laser Delivery of Topical Insulin Versus Platelet Rich Plasma in Treatment of Atrophic Post Acne Scars
Fractional CO2 Laser for Delivery of Topical Insulin Versus Platelet Rich Plasma in Treatment of Atrophic Post Acne Scars: a Split Face Comparative Study
1 other identifier
interventional
22
0 countries
N/A
Brief Summary
compare the efficacy and safety of treating atrophic post acne scars with topical insulin versus Platelet rich Plasma PRP combined with fractional ablative Co2 laser
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2024
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 28, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedStudy Start
First participant enrolled
November 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
September 19, 2024
September 1, 2024
2.6 years
June 28, 2024
September 7, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Efficacy and safety of treating atrophic post acne scars with topical insulin versus PRP combined with fractional ablative Co2 laser.
Scar assessment will be made using the Goodman and Baron Qualitative and Quantitative scarring system at baseline and at each visit to evaluate the clinical improvement.
5 months from the beginning of the treatment
Study Arms (1)
A prospective comparative split face study
ACTIVE COMPARATORInterventions
Comparative split face study: participants will be treated with fractional co2 laser on the whole face then applying topical insulin on the right side of the face and topical platelet rich plasma on the left side of the face.
Eligibility Criteria
You may qualify if:
- patients aged equal or more than 18 years with atrophic post acne scars.
You may not qualify if:
- pregnancy and lactation. Hypertrophic scars. patients suffering from aggressive inflammatory acne. kidney or liver disease. active infection at site of lesion. patients use medications that reduce tissue healing during the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Yan HM, Zhao HJ, Guo DY, Zhu PQ, Zhang CL, Jiang W. Gut microbiota alterations in moderate to severe acne vulgaris patients. J Dermatol. 2018 Oct;45(10):1166-1171. doi: 10.1111/1346-8138.14586. Epub 2018 Aug 13.
PMID: 30101990BACKGROUNDSzepietowska M, Dabrowska A, Nowak B, Skinderowicz K, Wilczynski B, Krajewski PK, Jankowska-Konsur A. Facial acne causes stigmatization among adolescents: A cross-sectional study. J Cosmet Dermatol. 2022 Dec;21(12):6815-6821. doi: 10.1111/jocd.15268. Epub 2022 Oct 14.
PMID: 35869826BACKGROUNDBhargava S, Cunha PR, Lee J, Kroumpouzos G. Acne Scarring Management: Systematic Review and Evaluation of the Evidence. Am J Clin Dermatol. 2018 Aug;19(4):459-477. doi: 10.1007/s40257-018-0358-5.
PMID: 29744784BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
June 28, 2024
First Posted
September 19, 2024
Study Start
November 1, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
July 1, 2027
Last Updated
September 19, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share